KIAWAH ISLAND, S.C. — An anterior keratoplasty technique using a decellularized Descemet’s membrane allograft yielded robust corneal epithelialization in patients with nonhealing ocular surface diseases, according to new research.
BrightMEM from Brightstar Therapeutics is a corneal allograft created from donated human cornea tissue that is designed to be transplanted onto the ocular surface. A study published in Cornea looked at postoperative outcomes of Descemet’s membrane anterior keratoplasty (DMAK) using the allograft.
“We wanted to look specifically at how well it supported healing,